Effects of nitric oxide synthase inhibition in lipopolysaccharide-induced sepsis in mice

Pharmacological Research

Volumn 38, Issue 5, 1998, Pages 405-411

  Tunçtan, Bahar ^a   Uludag, Orhan ^a   Altug, Sedat ^a   Abacioglu, Nrettin ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Lipopolysaccharide; Mice; Nitric oxide synthase; Nitrite; Septic shock; Serum

Indexed keywords

AMINOGUANIDINE; ARACHIDONIC ACID; ARGININE; CYTOKINE; ECONAZOLE; INDOMETACIN; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; NITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK;

EID: 0032211791     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0381     Document Type: Article

References (58)

1. 1. Zhang J, Snyder SH. Nitric oxide in the nervous system. Annu Rev Toxicol 1995; 35: 213-33.
2. 2. Förstermann U, Nakane M, Tracey WR, Pollock JS. Isoforms of nitric oxide synthase: functions in the cardiovascular system. Eur Heart J 1993; 14(Suppl. I): 10-15.
3. 3. Kolb H, Kolb-Bachofen V. Nitric oxide: a pathogenic factor in autoimmunity. Immunol Today 1992; 13(5): 157-60.
4. 4. Singh S, Evans TW. Nitric oxide, the biological mediator of the decade: fact or fiction? Eur Respir J 1997; 10: 699-707.
5. 5. Doughty L, Carcillo JA, Kaplan S, Janosky J. Plasma nitrite and nitrate concentrations and multiple organ failure in pediatric sepsis. Crit Care Med 1998; 26(1): 157-62.
6. 6. De Werra I, Jaccard C, Corradin SB, Chiolero R, Yersin B, Gallati H, Bohoun C, Baumgartner J-D, Glauser MP, Heumann D. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997; 25: 607-13.
7. 7. Harbrecht BG, Di Silvio M, Demetris AJ, Simmons RL, Billiar TR. Tumor necrosis factor-alpha regulates in vivo nitric oxide synthesis and induces liver injury during endotoxemia. Hepatology 1994; 20(4 Pt 1): 1055-60.
8. 8. Tracey WR, Tse J, Carter G. Lipolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Exp Ther 1995; 272(3): 1011-15.
9. 9. Reckelhoff JF, Kellum JA, Blanchard EJ, Bacon EE, Wesley AJ, Kruckeberg WC. Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging. Life Sci 1994; 55(24): 1895-902.
10. 10. Geller DA, Freeswick PD, Nguyen D, Nussler AK, Di Silvio M, Shapiro RA, Wang SC, Simmons RL, Billiar TR. Differential induction of nitric oxide production in hepatocytes during endotoxemia and acute-phase response. Arch Surg 1994; 129: 165-71.
11. 11. Lefer AM. Endotoxin, cytokines, and nitric oxide in shock: an editorial comment. Shock 1994; 1: 79-80.
12. 12. Hortelano S, Díaz Guerra MJ, Gonzalez García A, Leonardo E, Gamallo C, Boscá L, Martinez AC. Linomide administration to mice attenuates the induction of nitric oxide synthase elicited by lipopolysaccharide-activated macrophages and prevents nephritis in MRL/Mp-lpr/lpr mice. J Immunol 1997; 158(3): 1402-8.
13. 13. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91: 2046-50.
14. 14. Mitchell JA, Larkin S, Williams TJ. Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol 1995; 50: 1535-42.
15. 15. Szabó C. Alterations in nitric oxide production in various forms of circulatory shock. New Horizons 1995; 3: 2-32.
16. 16. Sautebin L, Ialenti A, Ianaro A, Di Rosa M. Modulation by nitric oxide of prostaglandin biosynthesis in the rat. Br J Pharmacol 1995; 114(2): 323-8.
17. 17. Zingarelli B, Southan GJ, Gilad E, O'Connor M, Salzman AL, Szabo C. The inhibitory effects of mercaptoalkylguanidines on cyclooxygenase activity. Br J Pharmacol 1997; 120: 357-66.
18. 18. Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF. Plasma tumor necrosis factor in patients with septic shock: mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis 1996; 141: 94-7.
19. 19. Fischer E, Van Zee KJ, Marano MA, Rock CS, Kenney JS, Pountsiaka DD, Dinarello CA; Lowry SF; Moldawer LL. Interleukin-1 receptor antagonist circulates in experimental inflammation and human disease. Blood 1992; 79: 2196-200.
20. 20. Nakae H, Endo S, Inada K, Takakuwa T, Kasai T, Yoshida M. Relationship between cytokines and leukotriene B4 in sepsis. Res Commun Chem Pathol Pharmacol 1994; 83: 151-6.
21. 21. Camussi G, Mariano F, Biancone L, De Martino A, Bussolati B, Montrucchio G, Tobias PS. Lipopolysaccharide-binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesengial and endothelial cells stimulated with lipopolysaccharide. J Immunol 1995; 155: 316-24.
22. 15N] nitrate in biological fluids. Anal Biochem 1982; 126: 131-8.
23. 23. Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 1998; 27: 8706-11.
24. 24. Corbett JA, McDaniel ML. Does nitric oxide mediate autoimmune destruction of beta-cells? Possible therapeutic interventions in IDDM. Diabetes 1992; 41(8): 897-903.
25. 25. Ruetten H, Thiemermann C. Prevention of the expression of inducible nitric oxide synthase by aminoguanidine or aminoethyl-isothiourea in macrophages and in the rat. Biochem Biophys Res Commun 1996; 225(2): 525-30.
26. 26. Numata M, Suzuki S, Miyazawa N, Miyashita A, Nagashima Y, Inoue S, Kaneko T, Okubo T. Inhibition of inducible nitric oxide synthase prevents LPS-induced acute lung injury in dogs. J Immunol 1998; 160(6): 3031-7.
27. 27. Salvemini D, Manning PT, Zwifel BS, Seibert K, Connor J, Currie MG, Needleman P, Masferrer JL. Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J Clin Invest 1995; 96: 301-8.
28. 28. Salvemini D, Misko TP, Seibert K, Masferrer JL, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 87: 2593-7.
29. 29. Hill JR, Corbett JA, Kwon G, Marshall CA, McDaniel ML. Nitric oxide regulates interleukin 1 bioactivity released from murine macrophages. J Biol Chem 1996; 271(37): 22672-8.
30. 30. Ertel W, Morrison MH, Wang P, Ba ZF, Ayala A, Chaudry IH. The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann Surg 1991; 214: 141-8.
31. 31. Cunha FQ, Assreuy J, Moss DW, Rees D, Leal LM, Moncada S, Carrier M, ODonnell CA, Liew FY. Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-alpha and IL-1-beta. Immunology 1994; 81(2): 211-15.
32. 32. Schulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD. The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha. Br J Pharmacol 1995; 114(1): 27-34.
33. 33. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991; 173(4): 1029-32.
34. 34. Gershenwald JE, Fong Y, Fahey TJ 3d, Calvano SE, Chizzonite R, Kilian PL, Lowry SF, Moldawer LL. Interleukin-1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 1990; 87: 4966-70.
35. 35. Wolff DJ, Datto GA, Samatovicz RA. The dual mode of inhibition of calmodulin-dependent nitric oxide synthase by antifungal imidazole agents. J Biol Chem 1993; 268(13): 9430-6.
36. 36. Bogle RG, Vallance P. Functional effects of econazole on inducible nitric oxide synthase: production of a calmodulin-dependent enzyme. Br J Pharmacol 1996; 117: 1053-8.
37. 37. Minnard EA, Shou J, Naama H, Cech A, Gallagher H, Daly JM. Inhibition of nitric oxide synthesis is detrimental during endotoxemia. Arch Surg 1994; 129: 142-8.
38. G-monomethyl-arginine. J Cardiovasc Pharmacol 1992; 20: S132-4.
39. 39. Kimura H, Miura S, Hiuchi H, Kurose I, Tsuzuki Y, Shigematsu T. Effect of chronic ethanol feeding on nitric oxide synthesis by rat Kupffer cells. Alcohol Clin Exp Res 1996; 20 (Suppl. 1): 69A-72A.
40. 40. Zhang Y, Crichton RR, Boelaert JR, Jorens PG, Herman PG, Ward RJ, Lallemand F, de Witte P. Decreased release of nitric oxide (NO) by alveolar macrophages after in vivo loading of rats with either iron or ethanol. Biochem Pharmacol 1998; 55(1): 21-5.
41. 41. Greenberg SS, Ouyang J, Zhao X, Xie J, Wang JF, Giles TD. Interaction of ethanol with inducible nitric oxide synthase messenger RNA and protein: direct effects on autacoids and endotoxin in vivo. J Pharmacol Exp Ther 1997; 282(2): 1044-54.
42. 42. Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol 1995; 114: 1335-42.
43. 2 production by vascular smooth muscle cells. Biochem Biophys Res Commun 1993; 194: 420-4.
44. 2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages. Biol Chem 1992; 373: 897-902.
45. 2 regulates inducible nitric oxide synthase in the murine macrophage cell line J774. Prostaglandins 1995; 49(2): 105-15.
46. 46. Pang L, Hoult JR. Induction of cyclooxygenase and nitric oxide synthase in endotoxin-activated J774 macrophages is differentially regulated by indomethacin: enhanced cyclooxygenase-2 protein expression but reduction of inducible nitric oxide synthase. Eur J Pharmacol 1996; 317(1): 151-5.
47. 47. Ferreira SH, Vane JR. New aspects of the mode of action of non-steroid anti-inflammatory drugs. Annu Rev Pharmacol 1974; 14: 57-73.
48. 48. Casey L, Balk R, Bone R. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Intern Med 1993; 119: 771-8.
49. 49. Ogata M, Matsumoto T, Kamochi M, Yoshida SI, Mizuguchi Y, Shigemmatsu A. Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice. Infect Immun 1992; 60(6): 2432-7.
50. 50. Pettipher ER, Wimberley DJ. Cyclooxygenase inhibitors enhance tumour necrosis factor production and mortality in murine endotoxic shock. Cytokine 1994; 6(5): 500-3.
51. 51. Evans T, Carpenter A, Silva A, Cohen J. Differential effects of monoclonal antibodies to tumor necrosis factor alpha and gamma interferon on induction of hepatic nitric oxide synthase in experimental gram-negative sepsis. Infect Immun 1992; 60(10): 4133-9.
52. 52. Payen D, Bernard C, Beloucif S. Nitric oxide in sepsis. In: Dorinsky PM, ed. Clinics in chest medicine: the sepsis syndrome. Philadelphia: WB Saunders, 1996: 333-50.
53. 53. Szabó C. The role of peroxynitrite in the pathophysiology of shock, inflammation and ischemia-reperfusion injury. Shock 1996; 6: 79-88.
54. 54. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-4.
55. 55. Wizemann T, Gardner C, Laskin J, Quinones S, Durham S, Goller N, Ohnishi T, Laskin D. Production of nitric oxide and peroxynitrite in the lung during acute endotoxemia. J Leukoc Biol 1994; 56: 759-68.
56. 56. Fleming I, Julou-Schaeffer G, Gray A, Parrat JR, Stocklet J-C. Evidence that and L-arginine/nitric oxide dependent elevation of tissue cyclic GMP content is involved in depression of vascular reactivity by endotoxin. Br J Pharmacol 1991; 103: 1047-52.
57. 57. Zingarelli B, Day BJ, Crapo JD, Salzman AL, Szabo C. The potential role of peroxynitrite in the vascular contractile and cellular energetic failure in endotoxic shock. Br J Pharmacol 1997; 120: 259-67.
58. 58. Demiryürek AT, Çakici İ, Kanzik İ. Peroxynitrite: a putative cytotoxin. Pharmacol Toxicol 1998; 82: 113-17.